Peer-reviewedCC BYClinical and translational allergy
Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema
- 1Charité – University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin
Related
- Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.
- Adverse health outcomes and patient and physician perspectives of attenuated androgen use in hereditary angioedema☆
- Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies☆
- Hereditary Angioedema Presenting With Acute Abdominal Symptoms and Progressive Upper Airway Compromise: A Case Report.
- Hereditary Angioedema with Normal C1-Inhibitor in Children: Diagnostic Challenges, Novel Mutations in MYOF, F12, and HS3ST6, and the Role of Bioinformatics Analysis
BibTeX
@article{magerl2026experiences,
title = {{Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema}},
author = {Markus Magerl and Kathrin Schön and Janine Ruhe and Felix Aulenbacher and Leonie Shirin Herzog and Thomas Buttgereit},
journal = {Clinical and translational allergy},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13654816},
note = {CC BY},
}
RIS
TY - JOUR
TI - Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema
AU - Markus Magerl
AU - Kathrin Schön
AU - Janine Ruhe
AU - Felix Aulenbacher
AU - Leonie Shirin Herzog
AU - Thomas Buttgereit
PY - 2026
DA - 2026/10/01
JO - Clinical and translational allergy
UR - https://europepmc.org/article/PMC/PMC13654816
SN - 2045-7022
ER -